Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer.
Hey Min Lee, Zhao Zheng, Alexey Sorokin...
https://pubmed.ncbi.nlm.nih.gov/40611889/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-30
30
Participants Needed
16
Research Sites
N/A
Total Duration
Researchers are evaluating the safety, optimal dose, and effectiveness of a new drug called ZEN003694 combined with cetuximab and encorafenib in patients who have colorectal cancer that has returned, spread, or not responded to previous treatments. This phase 1 trial studies patients with metastatic colorectal cancer that carries a specific BRAF V600E mutation. ZEN003694 works by blocking BET proteins, which may slow tumor growth, while cetuximab and encorafenib are existing cancer treatments that affect tumor cell survival and immune response. Participants receive ZEN003694 orally once daily for 28 days per cycle, cetuximab through intravenous infusion on days 1 and 15, and encorafenib orally once daily for 28 days each cycle. In the dose-expansion part of the study, encorafenib starts on day 2 of the first cycle and then continues daily thereafter. Treatment cycles repeat every 28 days until the cancer progresses or side effects prevent further treatment. Patients may have biopsies at screening and during the study, as well as imaging scans like CT or MRI and heart function tests through echocardiography or MUGA. Throughout the trial, researchers collect blood samples and monitor patients regularly. After completing treatment, participants are followed every two months to assess outcomes such as the maximum tolerated dose and anti-tumor activity. The study also evaluates how the drugs affect tumor biology, drug levels in the body, and possible resistance mechanisms. Participation continues up to the point of disease progression or unacceptable side effects, with ongoing safety and response monitoring.
CONDITIONS
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Regimen | Current Standard of Care |
|---|---|---|
| What it is | A single‑arm investigational treatment combining oral BET bromodomain inhibitor ZEN003694 with cetuximab and encorafenib for patients with BRAF V600E metastatic colorectal cancer who have progressed after prior encorafenib‑cetuximab therapy | A regimen of encorafenib plus cetuximab combined with fluoropyrimidine‑based chemotherapy (e.g., mFOLFOX6) represents the current standard of care for first‑line treatment of BRAF V600E‑mutant metastatic colorectal cancer |
| Role in study | Investigational therapy given to all enrolled participants | This is not part of the trial but reflects a current practice benchmark |
| Primary use | To evaluate safety, dose and preliminary efficacy of adding ZEN003694 to established encorafenib and cetuximab backbone | Used as an established first‑line treatment to control disease and improve survival in BRAF V600E‑mutant metastatic colorectal cancer |
| How it is given or performed | ZEN003694 given orally, combined with cetuximab (IV) and encorafenib (oral), with biospecimen collection and imaging assessments | Encorafenib given orally, cetuximab given IV, plus fluoropyrimidine‑based chemotherapy (e.g., mFOLFOX6) given per standard schedules |
| Evidence status | Evidence limited to safety and dose‑finding; efficacy outcomes to be determined | Phase III data (BREAKWATER) show improved progression‑free and overall survival with chemo‑targeted triplet versus chemotherapy alone |
| Important limitations | As a single‑arm dose‑escalation study, lacks randomized comparator; safety and efficacy still uncertain | Benefit established in treatment‑naïve patients; applicability after prior encorafenib‑cetuximab exposure may differ |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits including biopsy and imaging
Duration - Varies by participant until disease progression or toxicity
Participants receive ZEN003694 orally daily, cetuximab intravenously on days 1 and 15, and encorafenib orally daily in 28-day cycles until disease progression or unacceptable side effects.
Treatment cycles every 28 days with regular visits for drug administration and monitoring
Duration - Up to 3 years
After treatment ends, participants are followed up every 2 months to monitor health and treatment outcomes.
Follow-up visits every 2 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Hey Min Lee, Zhao Zheng, Alexey Sorokin...
https://pubmed.ncbi.nlm.nih.gov/40611889/Hey Min Lee, Zhao Zheng, Alexey Sorokin...
https://pubmed.ncbi.nlm.nih.gov/42101296/National Cancer Institute (NCI)
Lead Sponsor